Related Experiment Video

Updated: Dec 7, 2025

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
11:38

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy

Published on: July 3, 2014

47.2K

Prevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer

Agneta Månsson Broberg1,2, Jürgen Geisler3, Suvi Tuohinen4

  • 1Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.

Current Heart Failure Reports
|September 26, 2020
PubMed

Insights

Cardiovascular side effects are a growing concern for breast cancer survivors. Managing cardiotoxicity through risk factor assessment and targeted therapies is crucial for long-term survival.

Area of Science:

  • Cardiology
  • Oncology
  • Pharmacology

Background:

  • Long-term breast cancer survival rates have improved significantly.
  • Cardiovascular complications are increasingly surpassing cancer-related mortality.
  • Cardiotoxicity is a critical concern in breast cancer treatment.

Purpose of the Study:

  • To review risk factors, prevention, detection, and management of cardiotoxicity in breast cancer patients.
  • Focus on left ventricular dysfunction and heart failure during cancer treatment.

Main Methods:

  • Review of current literature on cardiotoxicity in breast cancer treatment.
  • Analysis of risk factors associated with specific cancer therapies.
  • Evaluation of preventive and management strategies.

Main Results:

  • Anthracyclines and trastuzumab pose a substantial cardiotoxicity risk.
  • Beta-blockers and angiotensin antagonists show promise in treating cardiotoxicity.
  • Chest wall irradiation accelerates atherosclerosis and fibrosis.
  • Other therapies like CDK4/6 inhibitors have a lower cardiotoxicity risk profile.
  • Early detection methods using cardiac imaging and biomarkers are under investigation.

Conclusions:

  • Comprehensive cardiovascular risk assessment and individualized evaluation are essential for prevention and management.
  • Further clinical trials are urgently needed for early detection, cardioprevention, and management strategies.
  • Addressing cardiotoxicity is vital for improving long-term outcomes in breast cancer survivors.
Abstract

Keywords:
AnthracyclinesBreast cancerCardiotoxicityHeart failureRadiation therapyTrastuzumab

More Related Videos

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.0K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.8K

Related Concept Videos

Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
296
Mitral Regurgitation IV: Nursing Management01:28

Mitral Regurgitation IV: Nursing Management

Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
215
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
142
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
123
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
197
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
726